Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Clinical Data, Inc. Announces Approval Of Generic Name Vilazodone, First In A New Class Of Experimental Treatments For Depression
Clinical Data, Inc. (NASDAQ: CLDA) announced today that the United States Adopted Name Council (USAN) has approved the generic name vilazodone hydrochloride. Vilazodone, if approved, would represent a first-in-class drug for the treatment of depression, due to its novel dual mechanism of action as both a potent and selective serotonin reuptake inhibitor (SSRI) and a partial agonist of the 5-hydroxytryptamine 1a (5-HT1A) receptor. Thus, vilazodone combines first-line therapy for depression with 5-HT1A partial agonism, an accepted adjunctive treatment for depression and a first-line therapy for anxiety disorders. Clinical Data has recently completed the second of two positive Phase III registration studies. Results of these studies will form the basis of a new drug application (NDA) that the Company intends to submit with the U.S. Food and Drug Administration (FDA) by the end of 2009.

Abstinence-Only Sex Education Debate Has High Financial Stakes, Washington Times Opinion Piece Says
By proposing to reduce funding for abstinence-only sex education programs, "the Obama administration has reignited America"s sex education debate," Washington Times columnist Cheryl Wetzstein writes in an opinion piece. She says that the "usual answers" she receives from abstinence-only opponents when she asks about their criticism of the programs is that abstinence-only education "doesn"t work, it leaves kids ignorant about how to use birth control, it doesn"t serve gay kids, and (off the record) it"s just a return to the bad old days when unenlightened, sex-hating harpies ran sex education." According to Wetzstein, some proponents of abstinence-only programs believe that another factor -- which is "never mentioned" in the sex education debate -- "is how sexually active youth are part of the market for certain commercial sex- and disease-related products, and abstinent behavior reduces that market share."Wetzstein reports that she recently spoke with Pam Mullarkey, founder of Project SOS, who is "furious" that Presdient Obama"s budget proposal would reduce funding for abstinence-only programs and increase money for teen pregnancy prevention. Mullarkey claims that abstinence-only opponents "have spent so much money trying to destroy abstinence education" because "it directly costs them big bucks" if teens abstain. Wetzstein writes that she has "dim hopes for the survival of abstinence education as we"ve know it," concluding, "But should Congress decide to "follow the money," as Mrs. Mullarkey suggests, who knows what might turn up" (Wetzstein, Washington Times, 5/19).
News of the day
Subclinical Markers Predict Relapse In Juvenile Idiopathic Arthritis Post Methotrexate Withdrawal
Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status, according to a new study presented at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
Nutrition

Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment At Major Danish Hospital

A leading Danish cancer hospital has treated its first patient using RapidArc(R) radiotherapy after installing eight advanced radiotherapy treatment machines from Varian Medical Systems (NYSE: VAR) of Palo Alto, California. Herlev Hospital, to the north-west of Copenhagen, delivered the fast and efficient RapidArc treatment to a prostate cancer patient using a Clinac(R) iX linear accelerator. The treatment comes just two years after the hospital selected Varian to replace its entire treatment machine and software infrastructure because the equipment was unable to carry out advanced image-guided treatments. "We are delighted with the rapidity of implementation," says Poul Geertsen, head of radiotherapy at Herlev Hospital. "The transition from our previous equipment to an overall Varian solution has been smooth and has enabled us to be among the first hospitals in Europe to offer RapidArc treatments." "All our treatment personnel were pleased with the speed and ease of the first treatment and the patient responded well," adds Brian Holch Kristensen, chief physicist. "We now have RapidArc capability on six of our eight linear accelerators and we hope to soon routinely carry out more prostate treatments before expanding our RapidArc program to include other pelvic and head & neck treatments." RapidArc delivers a precise and efficient treatment in single or multiple arcs of the treatment machine around the patient and makes it possible to deliver image-guided IMRT times two to eight times faster than is possible with conventional IMRT. Faster treatments allow for greater precision, since there is less chance of patient or tumor movement during treatment delivery and, with less time on the treatment couch, also allow for greater patient comfort. "Without any previous experience with RapidArc we successfully treated the first patient within two weeks of the RapidArc installation," adds David Sjostrom, deputy chief physicist. "In order to routinely replace today"s standard IMRT treatments with RapidArc for all treatment sites, we now need to strengthen our collaboration with Varian and other RapidArc users. In the future, we are hoping RapidArc will prove to be the best choice of treatment both in terms of delivery time and quality." Herlev Hospital carries out 48,000 radiation treatments per annum, treating 3,000 new patients each year. All eight Varian accelerators at Herlev, ordered in May 2007, are equipped with the On-Board Imager(R) device for modern, real-time image guidance, which is integral to RapidArc treatments. IGRT enables clinicians to pinpoint the position of the tumor at the time of treatment, allowing more precise treatments and potentially fewer side effects. "Clinicians at Herlev wanted us to enable them to offer patients advanced image-guided treatments when Varian machines and software were selected to replace their previous equipment two years ago and I am very pleased that we have been able to meet their expectations of us," adds Sten Hornsleth, Varian"s Scandinavian country manager. "Herlev Hospital is now offering radiotherapy treatments that are among the most advanced in the world, which is good news for cancer patients in Denmark." About Varian Medical Systems Varian Medical Systems, Inc., of Palo Alto, California, is the world"s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, China, and Europe and in its 79 sales and support offices around the world. Varian Medical Systems, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009